Columbia Center for Translational Immunology, Columbia University Irving Medical Center, NY.
Department of Biostatistics, Columbia University Irving Medical Center, NY.
Transplantation. 2023 Jul 1;107(7):1580-1592. doi: 10.1097/TP.0000000000004472. Epub 2023 Jun 20.
Potentially harmful nonhuman leukocyte antigen antibodies have been identified in renal transplantation, including natural immunoglobulin G antibodies (Nabs) reactive to varied antigenic structures, including apoptotic cells.
In this retrospective, multicenter study, we assessed Nabs by reactivity to apoptotic cells in sera collected from 980 kidney transplant recipients across 4 centers to determine their association with graft outcomes.
Elevated pretransplant Nabs were associated with graft loss (hazard ratio [HR] 2.71; 95% confidence interval [CI], 1.15-6.39; P = 0.0232), the composite endpoint of graft loss or severe graft dysfunction (HR 2.40; 95% CI, 1.13-5.10; P = 0.0232), and T cell-mediated rejection (odds ratio [OR] 1.77; 95% CI, 1.07-3.02; P = 0.0310). High pretransplant Nabs together with donor-specific antibodies (DSAs) were associated with increased risk of composite outcomes (HR 6.31; 95% CI, 1.81-22.0; P = 0.0039). In patients with high pretransplant Nabs, the subsequent development of posttransplant Nabs was associated with both T cell-mediated rejection (OR 3.64; 95% CI, 1.61-8.36; P = 0.0021) and mixed rejection (OR 3.10; 95% CI, 1.02-9.75; P = 0.0473). Finally, elevated pre- and posttransplant Nabs combined with DSAs were associated with increased risk of composite outcomes (HR 3.97; 95% CI, 1.51-10.43; P = 0.0052) and T cell-mediated rejection (OR 7.28; 95% CI, 2.16-25.96; P = 0.0016).
The presence of pre- and posttransplant Nabs, together with DSAs, was associated with increased risk of poor graft outcomes and rejection after renal transplantation.
在肾移植中已鉴定出潜在的有害非人类白细胞抗原抗体,包括对各种抗原结构(包括凋亡细胞)有反应的天然免疫球蛋白 G 抗体(Nabs)。
在这项回顾性、多中心研究中,我们通过检测 4 个中心的 980 名肾移植受者血清中对凋亡细胞的反应来评估 Nabs,以确定其与移植物结局的关系。
移植前升高的 Nabs 与移植物丢失(危险比 [HR] 2.71;95%置信区间 [CI],1.15-6.39;P=0.0232)、移植物丢失或严重移植物功能障碍的复合终点(HR 2.40;95%CI,1.13-5.10;P=0.0232)和 T 细胞介导的排斥反应(比值比 [OR] 1.77;95%CI,1.07-3.02;P=0.0310)相关。高移植前 Nabs 加上供体特异性抗体(DSA)与复合结局的风险增加相关(HR 6.31;95%CI,1.81-22.0;P=0.0039)。在移植前 Nabs 升高的患者中,随后发生移植后 Nabs 与 T 细胞介导的排斥反应(OR 3.64;95%CI,1.61-8.36;P=0.0021)和混合排斥反应(OR 3.10;95%CI,1.02-9.75;P=0.0473)相关。最后,升高的移植前和移植后 Nabs 加上 DSA 与复合结局(HR 3.97;95%CI,1.51-10.43;P=0.0052)和 T 细胞介导的排斥反应(OR 7.28;95%CI,2.16-25.96;P=0.0016)的风险增加相关。
移植前和移植后 Nabs 的存在加上 DSA 与肾移植后不良移植物结局和排斥反应的风险增加相关。